Sutro’s XpressCF+® cell-free protein synthesis technology provides a rapid and powerful platform for the discovery and development of next-generation antibody-drug conjugates (ADCs) and innovative biotherapeutics. Historically, cell-free protein synthesis has encountered challenges such as low titers, scalability, robustness, supply of critical reagents, and cost. In this article, we discuss Sutro’s unique cell-free platform, focusing on its modular components enables the scale-up of cell-free protein synthesis from microliter to kiloliter. Additionally, we present case studies that demonstrate the platform’s efficacy in scaling processes to a commercial scale for XpressCF+® cell-free protein synthesis.
